Stockscreener 앱 받기
57.77
1.80%
1.02
시간 외 거래:
57.77
전일 마감가:
$56.75
열려 있는:
$56.64
하루 거래량:
1.43M
Relative Volume:
0.67
시가총액:
$11.09B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
21.48
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-0.86%
1개월 성능:
-6.72%
6개월 성능:
-18.85%
1년 성능:
-32.13%
1일 변동 폭
$56.58
$58.03
1주일 범위
$55.99
$59.79
52주 변동 폭
$52.93
$86.04
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
57.77 | 10.90B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin’s PKU drug shows nearly 50% blood Phe reduction in teens - Investing.com
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PR Newswire
Why is BioMarin Pharmaceutical Inc. stock going upInflation Watch & Fast Moving Market Watchlists - خودرو بانک
What is BioMarin Pharmaceutical Inc.’s book value per shareJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - خودرو بانک
What makes BioMarin Pharmaceutical Inc. stock price move sharply2025 Pullback Review & AI Driven Stock Reports - Newser
Is BioMarin Pharmaceutical Inc. stock influenced by commodity prices2025 Bull vs Bear & Detailed Earnings Play Strategies - خودرو بانک
What’s the outlook for BioMarin Pharmaceutical Inc.’s sector2025 Sector Review & Fast Moving Trade Plans - خودرو بانک
BioMarin Pharmaceutical Inc. stock daily chart insightsWeekly Trade Analysis & Verified Trade Idea Suggestions - Newser
Analyzing drawdowns of BioMarin Pharmaceutical Inc. with statistical toolsWeekly Trade Recap & Entry Point Confirmation Alerts - Newser
How to use a screener to detect BioMarin Pharmaceutical Inc. breakoutsJuly 2025 Technicals & Verified Entry Point Signals - Newser
Tick level data insight on BioMarin Pharmaceutical Inc. volatilityJuly 2025 PostEarnings & Technical Pattern Alert System - Newser
What moving averages say about BioMarin Pharmaceutical Inc.July 2025 Big Picture & Weekly High Return Stock Forecasts - Newser
BioMarin at Wells Fargo Conference: Strategic Focus on Rare Diseases - Investing.com
What machine learning models say about BioMarin Pharmaceutical Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - Newser
Will BioMarin Pharmaceutical Inc. bounce back from current supportJuly 2025 Action & Community Consensus Picks - Newser
Visual trend scoring systems applied to BioMarin Pharmaceutical Inc.2025 Year in Review & Technical Confirmation Trade Alerts - Newser
The Top 12 Companies Hiring in Biopharma Now - biospace.com
Technical signs of recovery in BioMarin Pharmaceutical Inc.July 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Will BioMarin Pharmaceutical Inc. price bounce be sustainableMarket Performance Recap & Real-Time Sentiment Analysis - Newser
Top chart patterns to watch in BioMarin Pharmaceutical Inc.Take Profit & Risk Adjusted Buy/Sell Alerts - Newser
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
BioMarin Pharmaceutical shares fall 1.15% after-hours following analyst presentation at Cantor Global. - AInvest
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BioMarin’s Strategic Position in the 2025 Healthcare Innovation Landscape - AInvest
Will BioMarin Pharmaceutical Inc. outperform small cap indexesPortfolio Update Report & Stock Market Timing Techniques - خودرو بانک
Can you recover from losses in BioMarin Pharmaceutical Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Intraday pattern recognizer results for BioMarin Pharmaceutical Inc.2025 Top Decliners & Verified Swing Trading Watchlist - Newser
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed? - 富途牛牛
Should I invest in BioMarin Pharmaceutical Inc. before earningsTrade Risk Assessment & AI Forecast Swing Trade Picks - خودرو بانک
Combining price and volume data for BioMarin Pharmaceutical Inc.Weekly Trend Summary & Risk Managed Investment Strategies - Newser
Applying Wyckoff theory to BioMarin Pharmaceutical Inc. stockWeekly Gains Report & Real-Time Market Sentiment Alerts - Newser
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - au.finance.yahoo.com
Should you wait for a breakout in BioMarin Pharmaceutical Inc.Trade Analysis Summary & AI Optimized Trade Strategies - Newser
Can you recover from losses in BioMarin Pharmaceutical IncJuly 2025 Volume & Real-Time Stock Price Movement Reports - Newser
Identifying reversal signals in BioMarin Pharmaceutical Inc.July 2025 Institutional & Weekly Top Performers Watchlists - Newser
Is BioMarin Pharmaceutical Inc. stock poised for growthMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):